June 20, 2024

INESSS recommends including Tecvayli 

On June 5, 2024, the Institut national d’excellence en santé et en services sociaux (INESSS) formally recommended to the Minister that Tecvayli (teclistamab) be included in the list of medications at treatment centres for the treatment of patients with relapsed or refractory multiple myeloma, subject to specific conditions.  

Read more here (in french only)…